Eilean Therapeutics Acquires Ness Therapeutics

Valerio Therapeutics Acquires Etherna Immunotherapies

August 17, 2026

Biotechnology

Valerio Therapeutics acquired 100% of Etherna Immunotherapies at an enterprise value of €30 million, funded through cash consideration and contributions of Etherna shares. The acquisition combines Valerio’s cell-targeting technology with Etherna’s RNA chemistry, lipid nanoparticle delivery and GMP manufacturing capabilities to build an integrated targeted RNA therapeutics platform.

Eli Lilly Acquires 4E Therapeutics

June 16, 2026

Pharmaceuticals

Eli Lilly and Company acquired Austin-based neuroscience company 4E Therapeutics to advance its non-opioid chronic pain pipeline. 4E is developing orally available MNK inhibitors targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons, including lead candidate 4ET1103 that entered human Phase 1 trials with a favorable safety profile.

Innova Therapeutics Acquires Enci Therapeutics

November 27, 2025

Biotechnology

Innova Therapeutics has completed the acquisition of Enci Therapeutics, adding Enci’s lead oncology program, IVT-8086, a first-in-class humanized monoclonal antibody targeting SFRP2, to its development pipeline. Financial terms were not disclosed; Innova said the program and associated IP (patents through at least 2042) will support development across multiple solid and hematologic cancers and a companion diagnostic is in development.

AbbVie Acquires Nimble Therapeutics in $200 Million Deal

January 23, 2025

Biotechnology

AbbVie announced and later completed the acquisition of Nimble Therapeutics for $200 million in cash at closing, plus interim funding and potential development milestone payments to Nimble shareholders. The deal adds Nimble’s preclinical oral peptide IL23R inhibitor for psoriasis/IBD and its proprietary peptide synthesis, screening, and optimization platform to strengthen AbbVie’s immunology pipeline and R&D capabilities.

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.

BioNTech Acquires Neon Therapeutics

January 16, 2020

Biotechnology

BioNTech SE will acquire Neon Therapeutics, Inc. in an all-stock transaction valued at approximately $67.0 million. Neon, a Cambridge-based developer of neoantigen-targeted T cell therapies, will become a wholly owned subsidiary of BioNTech to expand BioNTech’s T cell therapy capabilities and U.S. presence.